HANGZHOU, China – (BUSINESS WIRE) – Hangzhou Qihan Biotechnology Co., Ltd. (“Qihan” or “Qihan Biotechnology” or the “Company”) is an industry leader in applying multiplex genome editing technology to cell therapy and organ transplantation By. Announced the successful completion of Pre-B round financing of over US$16 million, invested by new investor Zhejiang Industrial Fund Co., Ltd., with other existing investors following in the investment. The funds from this round of financing, coupled with the company’s reserves, will provide sufficient financial support for Qihan’s rapid product iteration and global development of gene-edited stem cell products in the next four years.
Dr. Yang Luhan, founder and CEO of Qihan Biotech, said: “We are very grateful to our existing shareholders for their continued support and our new shareholder Zhejiang Industry Fund Co., Ltd. for their trust. There are still many core challenges in the field of off-the-shelf cell therapy. This issue has yet to be overcome, but the combination of gene editing and stem cell therapy has great potential to create products that serve a wide range of cancer patients. We will continue to leverage Qihan’s scientific research and talent advantages and work diligently to develop off-the-shelf cell therapy products , bringing long-term benefits to patients.”
About Qihan Biotechnology
Qihan Biotechnology is a biotechnology company that applies genome editing technology to develop new cell therapies and transplant organs. The company’s mission is to leverage high-throughput, multiplexable genome editing combined with expertise in transplantation immunology to create immune-privileged allogeneic cells and xenogeneic organs for use as therapies to treat cancer, organ failure and other complex medical conditions . Qihan Biotech, whose vision is to create a world where cell and organ therapies are universally accessible to patients, has raised multiple rounds of funding. The company has multiple products in different stages of development, among which QN-019a has received IND approval from China’s NMPA for the treatment of CD19-positive relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Qihan’s deep scientific experience and technological advancements enable the company to create cutting-edge cell therapy products. Qihan Biotechnology is headquartered in Hangzhou, China. For more information, please visit the company’s website www.qihanbio.com
This press release contains statements including, but not limited to, statements about Qihan’s research progress and/or related plans, its past, ongoing and planned research, and the potential of Qihan’s research candidates. These and any other statements in this press release are based on Qihan’s management’s current expectations regarding future events and are subject to a number of risks and uncertainties that could cause actual results to differ from those set forth in such statements. or imply material and adverse differences in results. There is a risk that there will be delays or difficulties in the development or conversion of these Fengqihan’s research candidates, and there is a risk that Fengqihan may stop or delay the research and development of any candidate for various reasons. Qihan provides the information in this press release as of the date hereof and undertakes no obligation to update any statements in this press release as a result of new information, future events or otherwise. The information contained in this article about treatments and related products is not intended as medical advice.
Qihan Biological Public Relations
Tel: +86 0571-83500380
Fax: +86 0571-83500370
Content provided by Business Wire. Toutiao is not responsible for the content provided or any links related to that content. Toutiao is not responsible for the accuracy, topicality or quality of the content.